Phase III trial results of novel triple combination pill for hypertension published in The Lancet
October 18, 2024 07:00 ET
|
George Medicines
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual...
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
September 24, 2024 07:00 ET
|
George Medicines
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
August 31, 2024 03:54 ET
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program
August 06, 2024 07:00 ET
|
George Medicines
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
April 29, 2024 07:00 ET
|
George Medicines
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
July 12, 2023 07:00 ET
|
George Medicines
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...
George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
September 07, 2022 03:00 ET
|
George Medicines
George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage...
George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes
July 20, 2022 07:00 ET
|
George Medicines
George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes GMRx4 is the second candidate to be prioritised in...
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
January 17, 2022 07:00 ET
|
George Medicines
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
January 17, 2022 02:00 ET
|
George Medicines
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...